Insmed grants inducement awards to 128 new employees

BRIDGEWATER, N.J., Sept. 4, 2026 /CourierPR/ -- Insmed Incorporated, a global biopharmaceutical company dedicated to delivering innovative therapies for serious diseases, has granted inducement awards to 128 new employees as part of its 2025 Inducement Plan. The awards, authorized by the company’s Compensation Committee, were made to attract and retain key talent.

On August 31, 2026, the new employees received a total of 115,320 restricted stock units (RSUs) and options to purchase 5,560 shares of Insmed common stock. The options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first anniversary of the grant date, and 12.5% vesting every six months thereafter. The RSUs, which have a four-year vesting schedule, will release 25% of the underlying shares on each anniversary of the grant date, provided the employees remain with Insmed.

The RSUs and options were granted at an exercise price of $121.82 per share, the closing trading price on the Nasdaq Global Select Market on the day of the grant. These inducement awards are in line with NASDAQ Listing Rule 5635(c)(4), ensuring compliance with regulatory requirements.

Insmed's commitment to excellence and its focus on delivering transformative therapies for patients with serious diseases continue to drive its growth. The company’s diverse portfolio includes approved therapies for chronic lung diseases and cutting-edge drug discovery projects. Insmed operates in three therapeutic areas: Respiratory, Immunology & Inflammation, and Neuro & Other Rare, and maintains offices and research locations across the United States, Europe, and Japan.

Headquartered in Bridgewater, New Jersey, Insmed has been recognized for its commitment to scientific advancement, consistently ranking as one of the best employers in the biopharmaceutical industry. The company’s research efforts are centered on developing advanced technologies, including gene therapy and AI-driven protein engineering, to address unmet medical needs.

Insmed’s ongoing initiatives and strategic growth plans underscore its dedication to improving patient outcomes and advancing the field of biopharmaceuticals.